deciphera®

Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

November 29, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 29, 2023-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 1:30 PM ET.

A live webcast of the fireside chat will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at https://investors.deciphera.com/events-presentations. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera's switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Israel, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20231129967583/en/

Investor Relations: Maghan Meyers Argot Partners Deciphera@argotpartners.com 212-600-1902

Media: David Rosen Argot Partners david.rosen@argotpartners.com 212-600-1902

Source: Deciphera Pharmaceuticals, Inc.